NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older - European Medical Journal

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older

Respiratory

COVID-19 Vaccine update: learn about the clinical efficacy and safety data for a new recombinant protein subunit COVID-19 vaccine approved and available in >35 countries. The video can be viewed at your convenience.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now